Biomarker: CIP2A

Histology type: endometrioid endometrial carcinoma

Country: China

Region: Binzhou

Followed up time :

Subgroup 1 name : Negative expression in EAC

Subgroup 1 number: 19

Subgroup 2 name: High expression in EAC;Low expression in EAC;

Subgroup 2 number: 79;52

Conclusion: CIP2A is overexpressed in endometrioid adenocarcinoma and CIP2A promotes the malignant growth and invasion,decrease apoptosis in entometrioid adenocarcinoma cell lines. These results validate that CIP2A plays an important role in the carcinogenesis of endometrioid adenocarcinoma and establishes CIP2A as a clinically relevant oncoprotein and may presents a promising therapeutic target for cancer treatment.

Sample type : tissue

Sample method: RT PCR/Immunohistochemical staining

Expression pattern : overexpressed

Expression elevation: Score of the product of staining intensity score and the percentage of positive tumor cells. Staining intensity was graded as 0 (no staining),1 (weak staining), 2 (moderate staining) and 3 (strong staining). Percentage scores were assigned as 0 (≤10% positive the tumor cells),1(10–25%),2(26%-50%),3(51%-75%) and 4(76%-100%). By assessing the SI, staining results of CIP2A were finally recorded as 0–1,negative (−); 2–5,low expression; ≥6, high expression.

Statictics: cutoff<45;cutoff>45

Cohort age: 18;132

Subgroup 1 age: 4;15

Subgroup 2 age: 9;5;43;74

Funtion description: CIP2A depletion attenuates cell proliferation, invasion, and facilitates apoptosis. Furthermore, CIP2A depletion increases caspase‐3 expression and inhibits c-Myc and cyclin D1 expression. Taken together, the data suggest that CIP2A is a crucial oncoprotein involved in cell proliferation and apoptosis, and may serve as a candidate target for cancer treatment.

Funtion Uniprot: Oncoprotein that inhibits PP2A and stabilizes MYC in human malignancies. Promotes anchorage-independent cell growth and tumor formation.

UniProt ID: Q8TCG1

UniProt Link: https://www.uniprot.org/uniprotkb/Q8TCG1/entry

Molecular function from UniProt:

Tissue specificity from UniProt: Expressed at low levels in most of the tissues. Overexpressed in head-and-neck squamous cell carcinomas (HNSCC). Present in liver cancer cells (at protein level).

Subcellular UniProt: #Cytoplasm #Membrane

Alternative name from UniProt:

Miscellaneous: Antibodies against CIP2A are present in sera from many patients with gastric or prostate cancer, suggesting that it may act as a marker for such cancers.

Gene name from HGNC: CIP2A (KIAA1524)

HPA link: https://www.proteinatlas.org/ENSG00000163507-CIP2A

Tissue specificity RNA from HPA: Tissue enhanced (bone marrow, lymphoid tissue)

Tissue expression from HPA: Cytoplasmic and membranous expression in most tissues.

Subcellular summary HPA Located in Plasma membrane, Cytosol (CCD Transcript)

Cancer prognostic summary HPA Prognostic marker in endometrial cancer (unfavorable), renal cancer (unfavorable) and pancreatic cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000163507-CIP2A/tissue

OMIM: 610643

OMIM link2: https://www.omim.org/entry/610643

HGNC ID: HGNC:29302

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:29302